Advice
in the absence of a submission from the holder of the marketing authorisation:
brentuximab vedotin (Adcetris®) is not recommended for use within NHSScotland.
Indication under review: treatment of adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma in combination with doxorubicin, vinblastine and dacarbazine.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.
Download detailed advice356KB (PDF)
Medicine details
- Medicine name:
- brentuximab vedotin (Adcetris)
- SMC ID:
- SMC2202
- Indication:
- Treatment of adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma in combination with doxorubicin, vinblastine and dacarbazine.
- Pharmaceutical company
- Takeda UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 10 June 2019